THE PROPHYLACTIC EFFECTS OF LATAMOXEF AGAINST THE POSTOPERATIVE INFECTIONS TO THE OPEN HEART SURGERY
-
- MATSUURA YUICHIRO
- Department of Thoracic and Cardiovascular Surgery, Hiroshima Prefectural Hospital
-
- TAMURA MUTSUO
- Department of Thoracic and Cardiovascular Surgery, Hiroshima Prefectural Hospital
-
- YAMASHINA HIDEKI
- Department of Thoracic and Cardiovascular Surgery, Hiroshima Prefectural Hospital
-
- HIGO MASANORI
- Department of Thoracic and Cardiovascular Surgery, Hiroshima Prefectural Hospital
-
- FUJII TAKANORI
- Department of Thoracic and Cardiovascular Surgery, Hiroshima Prefectural Hospital
-
- YAMAMOTO MASAHARU
- Department of Thoracic and Cardiovascular Surgery, Hiroshima Prefectural Hospital
-
- SHIMAMOTO HIROYUKI
- Department of Thoracic and Cardiovascular Surgery, Hiroshima Prefectural Hospital
-
- YAMADA HIDEO
- Shionogi Research Laboratory, Shionogi & Co., Ltd.
-
- OGUMA TAKAYOSHI
- Shionogi Research Laboratory, Shionogi & Co., Ltd.
-
- SHIMAMURA KENJI
- Shionogi Research Laboratory, Shionogi & Co., Ltd.
Bibliographic Information
- Other Title
-
- Latamoxefの開心術術後感染症に対する予防効果に関する研究
- STUDIES, ON THE PENETRATION OF LATAMOXEF INTO THE PERICARDIAL FLUID AND THE AURICLE OF HEART
- Latamoxefの心嚢液, 右心耳移行濃度の検討
Abstract
Latamoxef (LMOX, Siomarin® ) at a dose of 2g was intravenously administered to each of 23 patients undergoing the open heart surgery and the concentrations in serum, pericardial fluid and auricle of heart were measured. Pharmacokinetic observations are summarized below.<BR>1. The peak serum concentration (t=0) was 227. 3 μ g/ml and the serum half-life (T1/2β ) was 1. 74 hours.<BR>2. In pericardial fluid, LMOX reached the peak concentration of 28. 44 μ g/ml at 4. 9 hours and the half-life was 9. 99 hours.<BR>3. In auricle of heart, LMOX reached the peak concentration of 42. 78 μ g/g at 6. 9 minutes and the half-life was 1. 74 hours.<BR>4. It was shown that LMOX penetrates well into the pericardial fluid and the auricle of heart, and it is considered that their levels exceed the minimal inhibitory concentration against a majority of clinical isolates except Pseudomonas aeruginosa.
Journal
-
- The Japanese Journal of Antibiotics
-
The Japanese Journal of Antibiotics 39 (5), 1241-1249, 1986
Japan Antibiotics Research Association